Patent · US Active

Combined therapy for cystic fibrosis

US9132123B2 · kind B2 · utility

2Cited by

1References

8Claims

0Family size

Assignee

I.E.R.F.C. EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCH · IT

Inventors

Luigi Maiuri · Milano, IT
Valeria Raia · Milano, IT
Fabio Borella · Milano, IT
Guido Kroemer · Paris, FR

Key dates

Filing date	May 16, 2013
Grant date	Sep 15, 2015
Priority date	—
Expiry date	Jun 25, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ΔF508-CFTR mutation, and pharmaceutical compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.